Purpose The aim of this retrospective study was to determine if some features of baseline F-FDG PET features were assessed using one-way analysis of variance. Areas under the ROC curves (AUC) were used to quantify the discriminative power of the features significantly associated with clinical/histopathological characteristics. Results T3 tumours (>5 cm) exhibited higher textural heterogeneity in 18 F-FDG uptake than T2 tumours (AUC <0.75), whereas there were no significant differences in SUV max and SUV mean . Invasive ductal carcinoma showed higher SUV max values than invasive lobular carcinoma (p=0.008) but MATV, TLG and textural features were not discriminative. Grade 3 tumours had higher FDG uptake (AUC 0.779 for SUV max and 0.694 for TLG), and exhibited slightly higher regional heterogeneity (AUC 0.624). Hormone receptor-negative tumours had higher SUV values than oestrogen receptor-positive (ER-positive) and progesterone receptor-positive tumours, while heterogeneity patterns showed only low-level variation according to hormone receptor expression. HER-2 status was not associated with any of the image features. Finally, SUV max , SUV mean and TLG significantly differed among the three phenotype subgroups (HER2-positive, triple-negative and ER-positive/HER2-negative BCs), but MATVand heterogeneity metrics were not discriminative. Conclusion SUV parameters, MATV and textural features showed limited correlations with clinical and histopathological features. The three main BC subgroups differed in terms of SUVs and TLG but not in terms of MATV and heterogeneity. None of the PET-derived metrics offered high discriminative power. 
Introduction
18 F-FDG PET/CT is becoming increasingly important for staging patients with breast cancer (BC) with large or locally advanced disease [1, 2] . These patients usually receive neoadjuvant treatment (chemotherapy with or without targeted therapy or endocrine therapy), surgery, radiation therapy and sometimes adjuvant systemic treatment. However, BC comprises different phenotypes with different response rates to chemotherapy, different treatment options, and different prognoses [3] . In clinical practice, three main entities based on immunohistochemical analysis of the primary tumour biopsy are currently considered: oestrogen receptor (ER)-positive/ HER2-negative, HER2-positive and triple-negative [4] . Specific systemic treatments are used in each subgroup. For example, large or locally advanced HER2-positive BC are treated with neoadjuvant chemotherapy plus trastuzumab. Recent work has shown that dual inhibition of HER2 (trastuzumab+lapatinib or trastuzumab+ pertuzumab) improves the pathological complete response rate in this subtype of BC [5] . However, it also involves more severe side effects, and hence the importance of patient selection to reserve these novel treatments for patients with a poor prognosis.
The clinical and pathological characteristics of BC are currently used to guide treatment. For example, patients with lymph node involvement have a poorer prognosis than patients with no lymph node involvement (N0), and higher grade tumours are more aggressive than lower grade tumours. More recently genetic prognostic tests (e.g. oncotype DX in ER-positive tumours) have emerged as promising tools to individualize treatment. However, there is still room for other prognostic factors and 18 F-FDG imaging could provide some. It has been shown that high baseline 18 F-FDG uptake (maximum standardized uptake value, SUV max ) is associated with poor prognostic factors such as high ScarffBloom-Richardson (SBR) grade [6, 7] and worse survival [8] .
Recently PET-derived quantitative heterogeneity measurements have also emerged as potential prognostic factors in several cancer types. In BC, the results of one recent study suggested that texture analysis might be used, in addition to SUV max , as a new tool to assess the aggressiveness of invasive BC [9] . Another team has reported that heterogeneity is associated with survival in patients with invasive ductal carcinoma (IDC) [10] .
Our present study included a larger number of consecutive patients (171) with stage II or III BC. It was designed to investigate in detail the relationships among some clinical, histological and immunohistochemical BC prognostics factors and volumetric and heterogeneity PET measurements.
Materials and methods

Study design
We performed a retrospective analysis of data acquired prospectively in the ASAINT study, which examined the role of 18 F-FDG PET/CT in patients with stage II/III BC undergoing neoadjuvant chemotherapy in Saint-Louis hospital [1] . The present analysis included 171 consecutive patients with stage II/III BC. The first and last included patients underwent imaging during July 2007 and April 2013, respectively. Patients with distant metastases were not included. Stage I patients received primary surgery with sentinel lymph node biopsy, and PET/CT was not performed for these patients. The primary aim was to evaluate the correlations among a large panel of baseline 1 8 F-FDG PET imaging-derived features (encompassing volumetric and heterogeneity metrics) and clinical data (e.g. patient age, cTNM classification), histological and immunohistochemical parameters (e.g. tumour grade, hormone receptor expression) and BC phenotype subgroup (ER-positive/HER2-negative BC, HER2-positive BC and triple-negative BC). A secondary aim was to quantify the discriminative power of features found to be significant.
Tumour histology and immunohistochemistry
Core-needle biopsy performed before treatment was used for diagnosis. Tumours were graded using the modified SBR system. Tumours were considered ER-positive if at least 10 % of cells showed moderate or high positivity (2 or 3+). Progesterone receptor (PR) positivity was determined according to the same criteria. Tumours were considered to overexpress cerbB-2 oncoprotein (HER2-positive) if more than 30 % of invasive tumour cells showed definite membrane staining resulting in a so-called fish-net appearance [11] . Control by fluorescence in situ hybridization or silver in situ hybridization was done for ambiguous cases. Triple-negative BC was defined as ER-negative, PR-negative and HER2-negative. Tumours were subsequently classified according to phenotype: triple-negative, HER2-positive or ER-positive/HER2-negative.
F-FDG PET/CT imaging
Blood glucose level had to be <7 mmol/L and patients fasted for 6 h before intravenous injection of 5 MBq/kg of 18 F-FDG into the arm opposite the breast tumour. Imaging on a Gemini XL PET/CT scanner (germanium oxyorthosilicate-based PET, 16 slice Brilliance CT; Philips Medical Systems) was started 60 min after injection from the mid-thigh level to the base of the skull, with the arms raised. CT data were acquired first (120 kV, 100mAs, no contrast enhancement). PET emission data were acquired in three-dimensional mode (2 min per bed position). PET images were reconstructed with the default manufacturer-provided method: 3D row-action maximum likelihood algorithm (4×4×4 mm voxels) and CT-based attenuation correction, normalized to the injected activity and body weight, and then converted to SUV using the expression:[tracer concentration (kBq/mL)]/[injected activity (kBq)/patient body weight (g)].
PET-derived features
For each patient, the primary tumour was identified by a nuclear medicine specialist. Metabolically active tumour volumes (MATVs) of the primary tumours (not the involved lymph nodes) were automatically segmented using the fuzzy locally adaptive Bayesian (FLAB) algorithm that has previously been validated for both homogeneous and heterogeneous uptakes [12, 13] including in BC [14] . Total lesion glycolysis (TLG) was defined as the product of MATV and SUV mean , both obtained through the FLAB delineation. Heterogeneity of the PET uptake within the delineated MATV was quantified using two different methods. The first was the area under the curve of the cumulative histogram (CH AUC ), a method quantifying global tumour heterogeneity [15] . The second relies on textural features (TF) analysis. Five TFs were chosen on the basis. [16] [17] [18] [19] , and corresponding to the most robust with respect to partial volume effects [18] and segmentation [18] , reconstruction settings [20] , as well as test-retest physiological reproducibility [17] . All TFs were calculated after quantization involving 64 grey levels [17] [18] [19] . The TFs calculated using a co-occurrence matrix taking into account all 13 directions simultaneously without an averaging step [19] , were entropy (E) and dissimilarity (D), and also homogeneity (H) that was included for comparison with the findings of a recent study [9] . They quantify local heterogeneity at the scale of a voxel and its neighbourhood. TFs calculated using size-zone matrices included high-intensity large area emphasis (HILAE) and zone percentage (ZP). They quantify regional heterogeneity based on the respective sizes and intensities of groups of voxels. Figure 1 provides an example of two tumours with different levels of heterogeneity.
Because heterogeneity quantification in PET images using TFs can be confounded by tumour volume effects in smallvolume tumours, especially those <10 cm 3 [19, 21] , we also performed a subanalysis for MATVs >10 cm 3 .
Statistical analysis
Statistical analyses were performed using MedCalc™ (MedCalc Software, Ostend, Belgium). The feature values were expressed using medians ±standard deviations (SD) and range (min-max). Correlations among PET features were assessed using Spearman's rank coefficient (rho). The associations between each PET feature and clinical, histopathological factors and subgroups (TNBC, HER2-positive, ER-positive/HER2-negative) were assessed using one-way analysis of variance. For distributions not normally distributed, log transformation was first applied. For ER, PR and HER2 status, positive cases were compared with negative cases. Tumours of low and intermediate grade (1/2) were compared with high-grade tumours (grade 3). T1 and T2 tumours (clinically estimated at ≤5 cm diameter) were compared with T3 tumours (>5 cm), excluding T4 from the analysis because of the specificity of T4 staging that is not based on tumour size. N0 cases were compared to cases with clinical and cases with clinical lymph node involvement (N1, N2 or N3) were compared. The three main histology types of this series (invasive ductal, lobular, and metaplastic carcinoma) were compared. The discriminative power of each PET feature significantly associated with a clinical or a histopathological factor or a BC subgroup was quantified by determining the area under the receiver operating characteristic curve (AUC).
All tests were two-sided and p values <0.05 were considered statistically significant, with correction for multiple testing being performed using the false discovery rate Benjamini-Hochberg step-up procedure. This procedure consists of declaring positive discoveries at level α (here α=0.05), among the k=1…K tested variables (here K=10) ordered (increasing order) according to their p values, those ranked above the one satisfying the condition p(k)≤k/K× α [22] . 
Associations between clinical factors and PET features
Patient age was not found to be associated with any PET feature ( Table 2 ). The median SUV max was 7.6 in women ≤50 years of age and 6.9 in women >50 years of age (p= 0.09). T3 tumours exhibited levels of 18 Fig. 2 ). Grade 3 tumours also showed slightly higher regional heterogeneity (HILAE 927±307 for grade 3 vs. 792±233 for grade 1 and grade 2; p=0.012), whereas differences in terms of volume (p=0.034) and local heterogeneity (E, p=0.04) did not reach statistical significance after correction for multiple testing. Finally, the AUCs of the associations with grade 3 tumours were 0.779 for SUV max and 0.769 for SUV mean , and <0.7 for TLG and HILAE.
ER positivity and PR positivity were both associated with significantly (p≤0.001) lower SUVs (SUV max 6.4±3.8 for ). Lower local heterogeneity (D and H) was seen in hormone-positive BC (Table 2) . PR-positive tumours also exhibited lower E (6.9 ± 0.6 vs. 7.1 ± 0.5, p = 0.025). Overlaps between ER/PRpositive and ER/PR-negative tumours were very important, with AUCs ≤0.67 (obtained with SUV max ).
Only SUV max , SUV mean and TLG were significantly associated (p≤0.001) with the three BC subgroups: ER-positive/ HER2-negative, HER2-positive and triple-negative (Fig. 3a) . Triple-negative BC showed the higher SUV max (9.8±6.2) than HER2-positive BC (7.0±4.5) and ER-positive/HER2-negative BC (6.2±3.6). Neither MATV (Fig. 3b) nor any of the derived heterogeneity quantification metrics (global, regional or local scales) were found to be significantly different among the three BC subgroups after correction for multiple testing (Table 2) . Results were similar when restricting the analysis to the 89 patients with MATV >10 cm 3 , although the statistical significance of SUV max (p=0.045) and SUV mean (p=0.033) was lost after correction for multiple testing.
Among the three PET features (SUV max , SUV mean and TLG) found to be significantly associated with BC subgroup, SUV max offered the highest (yet still limited) power to discriminate patients with triple-negative BC (0.713) and those with ER-positive/HER2-negative BC (0.675) (Fig. 4b, c) . SUV mean had slightly lower discriminative power, whereas TLG was least discriminative. Regarding the identification of patients with HER2-positive tumours, none of the PET features had discriminative power (all AUCs ≤0.547; Fig. 4a ).
Discussion
Recently interest in PET image-derived features beyond the usual SUV measurements in oncology, including volumetric, shape and heterogeneity metrics, has been increasing [16, 23] , with special reference to the comprehensive quantification of tumour phenotypes, popularly termed "radiomics" [24, 25] . It has recently been shown that cancer subgroups can be noninvasively identified using image-based radiomic features extracted from dosimetry planning CT images in large cohorts of patients with non-small-cell lung cancer and head and neck cancer [24] . Some of these new heterogeneity and shape metrics in 18 F-FDG PET images have shown some value in predicting response to therapy and as prognostic factors in several solid tumours such as head and neck [26] , oesophageal [16] and lung cancer [27, 28] .
BC is a heterogeneous class of tumour. The various BC subgroups differ in biology profiles, treatment possibilities, and outcomes. We have previously reported that high FDG uptake is correlated with histologically and biologically poor prognostic factors in BC. Notably, we have found that 18 F-FDG uptake is higher in triple-negative BC than in ERpositive tumours [6] and triple-negative BC has a poorer prognosis [29] .
FDG uptake distribution has been associated with underlying physiopathological characteristics such as vascularization, perfusion, tumour aggressiveness, necrosis, hypoxia and gene expression [30] [31] [32] [33] [34] . We therefore hypothesized that significantly different values of PET image-derived heterogeneity quantification features may be observed between the different BC molecular subgroups, assuming these subgroups have different underlying physiopathological properties.
Only a few studies have investigated 18 F-FDG PET imaging heterogeneity features in BC [9, 10] . A recent study investigated the relationship between 18 F-FDG heterogeneity quantification with TFs and histopathological factors, suggesting that tumour heterogeneity measured on 18 F-FDG PET/CT was higher in invasive BC with pathological factors indicating a poor prognosis, and that texture analysis might be used, in addition to SUV max , as a new tool to assess invasive BC aggressiveness [9] . The combination of SUV max with heterogeneity TFs indeed led to the identification of the 13 patients with triple-negative BC among the 54 patients with BC with an AUC of 0.83 instead of 0.77 when using SUV max only, although this improvement was not significant [9] . The patient population was somewhat different from that in our study since it included 14 patients (26 %) with distant metastases, while we did not include patients with distant metastases. Nonetheless, our results regarding SUV max are congruent with data from the previous study and others [6, 9] . On the other hand, our data suggest that none of the heterogeneity quantification metrics provided any added power in comparison with SUV max for differentiating BC subgroups. We used the same 64 grey-level quantization and the same or similar TFs.
Another recent study investigated the heterogeneity of 18 F-FDG uptake in 123 patients with BC, and showed the prognostic value of MATV and heterogeneity, and that these two PET features are associated with clinical outcome [10] . However, in that study the "heterogeneity factor" used was defined as "a derivative of a volume threshold function from 40 % to 80 % of the SUV max " and was reported to be highly correlated with MATV (r=0.96) [10] . On the one hand, this heterogeneity factor is therefore only a surrogate measurement of volume and led to exactly the same survival curves. It cannot be considered as a measurement of intratumoral heterogeneity. On the other hand, we also included an alternative heterogeneity quantification metric (CH AUC ) [15] , which similarly failed to exhibit any correlation with BC subgroups. The fact that textural analysis and the alternative CH AUC both failed to capture any correlation strengthens our overall conclusions.
In the present study, the correlation between MATV and its derived heterogeneity quantification ranged from 0.06 (for HILAE) to 0.88 (for D) depending on the metric, as previously shown [18, 19] . Heterogeneity quantification may be more relevant and less correlated with the volume when it is calculated for large tumour volumes [19, 21] . This is why we also performed a separate analysis in the 89 patients with tumour volumes >10 cm 3 , a threshold value we have previously identified with respect to the correlation of MATV and TFs [19] . However, the results of this separate analysis were not different.
We evaluated the relationship between several PET-derived parameters and BC cancer subgroups based on immunohistochemical tests. The phenotype distribution in our series of 171 patients with stage II/III BC (triple-negative 32 %, HER2-positive 19 %, ER-positive/HER2-negative 49 %) was similar to that found in other studies [35, 36] . Our results suggest that the heterogeneity and variability in terms of BC phenotype subgroups determined by immunohistochemistry do not necessarily translate into measurable and significant differences in terms of heterogeneity features on 18 F-FDG PET images. Conversely, the usual SUV metrics exhibit significant differences, with higher SUV max uptake in triple-negative BC than in ER-positive/HER2-negative and HER2-positive BC. However, their discriminative power was limited, with substantial overlaps between the three subgroups (Fig. 3) . Our results show that 18 F-FDG PET/CT does not provide quantitative measurements with enough discriminative power to replace biopsies and molecular analyses for BC subgroup classification.
The present results corroborate our previous findings that tumours with biological factors indicating a poor prognosis such as hormone receptor negativity, triple-negativity and high grade have higher levels of 18 F-FDG uptake (SUV values) [6] . The relationships between these prognostic factors and image heterogeneity features are less clear-cut, although some correlation was observed, especially with hormone receptor expression (Table 2) .
Our study had some limitations. It was a retrospective analysis of prospectively collected patient data from a single institution. Involved lymph nodes were not included in the analysis, as only primary tumours were quantified, although the correlation between the various metrics quantifying heterogeneity in the primary tumours and lymph node involvement was assessed. The FLAB algorithm was used to determine the MATVs of primary tumours automatically. This algorithm optimized for PET imaging has demonstrated high accuracy, robustness and reproducibility in clinical practice. Although the FLAB algorithm was used in order to include the entire area of heterogeneous uptake of the primary tumour, voxels with low SUV similar to background levels of uptake (such as areas of necrosis) could have been excluded from the volume used for heterogeneity quantification if they were not in the centre of the tumour volume, which is rare.
It should be emphasized that imaging of breast tumours can be affected by respiratory motion. TFs blurred by respiratory motion in the reconstructed 3D static image can be better resolved by 4D PET imaging [37] . Combined with the limited spatial resolution of PET, this greatly limits the level of heterogeneity detail that can be captured by any image analysis method. Although time-of-flight imaging may not significantly enhance the heterogeneity detail in PET images since it mostly enhances signal-to-noise ratio rather than spatial resolution, using a dedicated breast PET (positron emission mammography) scanner could improve the evaluation of heterogeneity compared to standard PET/CT [38, 39] .
We chose to categorize patients into three subgroups (triple-negative, HER2-positive and ER-positive/HER2-negative), which are based on immunohistochemistry tests and allow groups of patients with homogeneous treatments to be defined. Other categorizations could be considered: hormonepositive breast tumours can be dichotomized into luminal A (ER-positive/HER2-negative, with low grade and low proliferation) and luminal B (which regroups highly proliferative ER-positive/HER2-negative breast carcinoma and some ERp o s i t i v e / H E R 2 -p o s i t i v e t u m o u r s ) . T h i s f u r t h e r dichotomization could alter our results, as recent studies have indicated that luminal A tumours are less 18 F-FDG-avid than luminal B tumours [40] . Similar to the extended analysis of lymph node heterogeneity quantification, this could be the subject of future investigations, although it is unlikely that the addition of another BC subgroup would allow the discriminative power of PET features to be improved. Finally, the impact of heterogeneity metrics on other PET tracers might be of interest in BC [41] and should be further evaluated.
Conclusion
This study confirmed the association between high values of SUV max in primary BC tumours and some biological and immunohistochemical poor prognostic factors. In particular high-grade tumours exhibited higher 18 F-FDG uptake than low-grade and intermediate-grade tumours. SUV max was higher in triple-negative tumours than in hormone-positive BC. In this series of stage II/III BC, tumour size had no significant impact on 18 F-FDG uptake with SUV max values in T3 tumours (>5 cm) similar to those in T2 tumours. T3 tumours exhibited more heterogeneous 18 F-FDG uptake than T2 tumours, although overlap was substantial (AUCs <0.75). Tumour grade was not found to be associated with volumetric metrics and a limited association was seen with regional heterogeneity. Oestrogen and progesterone receptor expression were associated with several heterogeneity patterns, but the discriminative power was limited. Finally, the three different BC subgroups (ER-positive/HER2-negative, HER2-positive and triple-negative) did not show any significant and measurable differences in levels of heterogeneity.
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